LIfT BioSciences Awarded Innovate UK Grant to Accelerate Product Development of New IMAN Cell Therapy Variants
Groundbreaking in vivo studies will be progressed to explore the impact of IMAN cell therapies in solid tumour and immunology models...
May 16, 2024
LIfT demonstrates how IMANs rapidly infiltrate tumours and recruit in other immune cells to destroy solid tumours together
LIfT’s CEO Alex Blyth detailed how Immuno-Modulatory Alpha Neutrophils (IMANs) outperform traditional neutrophils by rapidly infiltrating...
Apr 10, 2024
Dr. Bo Rode Hansen explains why he joined LIfT as a Non-Executive Director
We recently caught up with Dr. Bo Rode Hansen, a Non-Executive Director at LIfT, to find out what motivated him to join LIfT and why he...
Mar 5, 2024
LIfT’s CEO challenges out dated thinking that therapies focused on T-Cells alone are enough to achieve complete remission in most solid tumours
During a presentation at the Biotech Showcase, our CEO, Alex Blyth challenged the current view that T-cells can do it all, highlighting...
Feb 22, 2024
LIfT BioSciences appoints Dr Bo Rode Hansen and Dr Marco Gottardis to its Board of Directors
London, 21st December 2023 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech company bringing to market a...
Dec 21, 2023
